PEPN2113: A Phase 1 and pharmacokinetic study of Uproleselan (GMI-1271, IND #139758, NSC #801708) in combination with fludarabine and cytarabine for patients with acute myeloid leukemia, myelodysplastic syndrome or mixed phenotype acute leukemia that expresses E-selectin ligand on the cell membrane and is in second or greater relapse or that is refractory to relapse therapy

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- patient must be enrolled on APAL2020SC (NCT04726241) - patients must be between 1 and 17 years of age at the time of study enrollment - patients, with or without Down syndrome (DS), and with de novo acute myeloid leukemia, therapy-related acute myeloid leukemia, myelodysplastic syndrome or mixed phenotype acute leukemia that expresses E-selectin ligand on the cell membrane - second or greater relapse or refractory AML OR refractory myelodysplastic syndrome (MDS) OR mixed phenotype acute leukemia (MPAL) - see link to clinicaltrials.gov for complete criteria

Exclusion Criteria:

- patients who are currently receiving another investigational drug are not eligible - patients who are currently receiving other anti-cancer agents are not eligible except patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy - study staff will review additional exclusion criteria

Conditions & Interventions

Conditions:
Cancer, Cancer
Keywords:
AML, Myelodysplastic Syndrome Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia

More Information

Description: A Phase 1 and pharmacokinetic study of Uproleselan (GMI-1271, IND #139758, NSC #801708) in combination with fludarabine and cytarabine for patients with acute myeloid leukemia, myelodysplastic syndrome or mixed phenotype acute leukemia that expresses E-selectin ligand on the cell membrane and is in second or greater relapse or that is refractory to relapse therapy
Study Contact: Allison Fullenkamp - fulle631@umn.edu
Principal Investigator: Emily Greengard
IRB Number: SITE00001697